Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 1/2 interventional trial evaluating the safety and potential efficacy of 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma, including DLBCL, PMBCL, transformed FL, and MCL. The study compares the 3-month objective response rate and complete remission rate of the experimental cohort with a historical control group from prior research. Eligible participants have CD19-positive tumors, have failed at least two prior lines of therapy, and have measurable disease. Treatment involves infusion of the memory-enhanced CAR-T cells, with ongoing monitoring for safety and response. The trial is sponsored by Second Affiliated Hospital, Zhejiang University School of Medicine, and conducted at a single center in Hangzhou, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily participate in this study and sign the informed consent form.
2. Age range: 18 - 75 years old. Gender is not restricted.
3. Histologically confirmed large B-cell lymphoma, including: diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (tFL), and mantle cell lymphoma (MCL).
4. CD19-positive (as determined by immunohistochemistry or flow cytometry; based on the most recent tumor biopsy results).
5. Definition of relapsed/refractory: Failure to achieve complete remission (CR) after at least two lines of therapy (which must include a CD20 monoclonal antibody and an anthracycline); or disease progression during any course of treatment; or relapse/progression within 12 months after autologous hematopoietic stem cell transplantation.
6. At least one measurable lesion: any lymph node lesion with a longest dimension \>1.5 cm, or any extranodal lesion with a longest dimension \>1.0 cm, and the lesion shows uptake on PET-CT (SUV greater than the hepatic pool).
7. Absolute neutrophil count in peripheral blood ≥ 1,000/μL; platelet count ≥ 45,000/μL.
8. Cardiac, hepatic, and renal function: creatinine \< 1.5 mg/dL; ALT/AST ≤ 2.5 times the upper limit of normal; total bilirubin \< 1.5 mg/dL; ejection fraction ≥ 50%.
9. Possess sufficient cognitive capacity to voluntarily sign the informed consent form.
10. Participants of reproductive potential must be willing to use effective contraception (from the time of signing the informed consent form until 12 months after CAR-T infusion).
11. The investigator estimates a life expectancy of at least 4 months.
12. Willing to comply with the schedule of visits, dosing regimen, laboratory tests, and other trial procedures.

Exclusion Criteria:

1. History of other malignant tumors (excluding cured basal cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, etc.).
2. Autologous hematopoietic stem cell transplantation within the past 6 weeks.
3. Any targeted CAR-T therapy within 3 months prior to this CAR-T treatment.
4. Patients who have previously received PD-1 monoclonal antibodies must have a washout period of ≥3 months before enrollment.
5. Received cytotoxic drugs, glucocorticoids (except for prednisone-equivalent doses of ≤10 mg/day), or other targeted therapies within 2 weeks prior to cell collection.
6. Active autoimmune diseases (e.g., systemic lupus erythematosus, inflammatory bowel disease, etc.).
7. Uncontrolled active bacterial, fungal, or viral infections.
8. HIV infection, syphilis; active hepatitis B or C: Hepatitis B: HBsAg-positive and HBV-DNA ≥ 1,000 IU/mL; Hepatitis C: HCV RNA-positive and abnormal liver function.
9. Known central nervous system lymphoma (confirmed by brain MRI or CT and cerebrospinal fluid examination).

Where it's running

• The Second Affiliated Hospital,School of Medicine,Zhejiang University, Hangzhou, Zhejiang 310009
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Wenbin Qian,Professor
• Email: qianwb@zju.edu.cn
• Phone: +86 13605801032

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma

  This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.

  Recruiting Phase 1/2 TICAROS Co., Ltd. · Seoul, Seoul · NCT07473167

• Treatment for relapsed B cell lymphoma using CAR-NK and CAR-T cells

  This study is testing a new treatment for people with relapsed B cell lymphoma that uses two types of immune cells, CAR-NK and CAR-T, to see if it helps them feel better.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06464861

• Evaluation of CAR-T cell therapy in certain blood cancers

  This study is testing how well CAR-T cell therapy works and lasts in patients with certain types of blood cancers, while also looking for signs that could predict how they respond to treatment and any side effects they might have.

  Recruiting Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Brescia · NCT05366569

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.